Mgr. Michal Šmída, Dr. rer. nat.
Research Group Leader Junior, Michal Šmída Research Group
Office: bldg. E35/186
Kamenice 753/5
625 00 Brno
Phone: | +420 532 23 5494 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 74
2021
-
Identification of biomarkers and escape mechanisms for CAR-T cell therapy in chronic lymphocytic leukemia.
Year: 2021, type:
-
In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation.
Year: 2021, type: Conference abstract
-
Kongenitální neutropenie u dětí a dospělých
Transfúze a hematologie dnes, year: 2021, volume: 27, edition: 4, DOI
-
Open Week
Year: 2021, type: Popularization text
2020
-
CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
Plos one, year: 2020, volume: 15, edition: 3, DOI
-
Combination of epigenetic drug screen and CRISPR knockout screen as an unbiased approach to reveal possible CD20 therapy improvement
Year: 2020, type: Conference abstract
-
Combination of epigenetic drug screen and CRISPR knockout screen revealed involvement of aurora kinases and Cullin 3 in CD20 regulation
Year: 2020, type: Conference abstract
-
CRISPR/CAS9 technology: a useful tool in the study of chronic lymphocytic leukemia
Year: 2020, type: Conference abstract
-
Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells
Year: 2020, type: Conference abstract
-
Genome-wide CRISPR/Cas9 screening reveals novel target genes, whose inactivation is able to upregulate surface expression of immunotherapy target CD20
Year: 2020, type: Conference abstract